Last updated: September 3, 2026
Calfactant, marketed as Infasurf, is a mature bovine-derived pulmonary surfactant used to prevent and treat respiratory distress syndrome (RDS) in premature infants. Its FDA exclusivity and core patent protection have expired. The product remains commercially relevant because neonatal intensive-care units require immediate surfactant therapy, but revenue growth is constrained by a small patient population, hospital purchasing pressure, and competition from poractant alfa and beractant.
Standalone sales, operating margins, and product-level profitability are not publicly disclosed. The financial outlook is therefore best assessed through market position, demand stability, competitive pricing, manufacturing complexity, and regulatory barriers.
What is calfactant and how is Infasurf used?
Calfactant is a natural pulmonary surfactant derived from bovine lung lavage. It contains phospholipids and the hydrophobic surfactant proteins SP-B and SP-C, which reduce alveolar surface tension and improve lung compliance in premature infants.
| Attribute |
Calfactant |
| Brand |
Infasurf |
| Active material |
Bovine lung-derived pulmonary surfactant |
| FDA application |
NDA 20-972 |
| Initial FDA approval |
1998 |
| Primary indication |
Prevention and treatment of neonatal RDS |
| Route |
Intratracheal administration |
| Typical labeled dose |
3 mL/kg per dose |
| Patient population |
Premature infants at risk of or diagnosed with RDS |
| U.S. commercial company |
ONY Biotech |
| Product category |
Neonatal pulmonary surfactant |
The product is administered through an endotracheal tube in the delivery room or neonatal intensive-care unit. Its use is concentrated in hospitals with high-risk obstetric and neonatal services.
FDA labeling permits prophylactic use in premature infants at substantial risk of RDS and rescue treatment in infants who develop RDS. The treatment setting requires trained staff, respiratory support equipment, and rapid access to the product, which limits substitution based solely on retail price. (U.S. Food and Drug Administration, 2023a)
How large is the calfactant market?
The global neonatal surfactant market is a niche hospital market rather than a broad primary-care pharmaceutical category. Demand is driven by premature births, neonatal intensive-care capacity, clinical protocols, and regional access to surfactant therapy.
Public sources do not disclose standalone Infasurf revenue or a verified product-level global market share. ONY Biotech is privately held, and available public company information does not provide audited Infasurf sales, gross margin, or geographic revenue splits.
The commercial market has several structural characteristics:
- Demand is medically necessary and relatively resilient. Infants with significant RDS generally require urgent treatment.
- Patient volume is limited. Sales depend on the annual number of premature births and the proportion treated with surfactant.
- Hospital concentration is high. Purchasing decisions are made by integrated delivery networks, hospital systems, neonatal pharmacies, and group purchasing organizations.
- Product selection is protocol-driven. Neonatologists consider dose volume, evidence base, administration logistics, local formulary policy, and supply reliability.
- Inventory requirements are stringent. Hospitals must maintain stock despite uncertain daily demand, creating a service and supply-chain advantage for established manufacturers.
The commercial ceiling is therefore determined less by broad population growth than by share retention, contracting, replacement of competing surfactants, and expansion in countries with under-treated neonatal RDS.
Who competes with calfactant in neonatal surfactants?
Calfactant competes primarily with poractant alfa, sold as Curosurf, and beractant, sold as Survanta.
| Product |
Active material |
Commercial sponsor |
Competitive characteristics |
| Infasurf |
Calfactant |
ONY Biotech |
Bovine-derived; 3 mL/kg labeled dose; established U.S. NICU use |
| Curosurf |
Poractant alfa |
Chiesi |
Porcine-derived; lower initial volume at the 200 mg/kg dose; strong international presence |
| Survanta |
Beractant |
AbbVie |
Bovine-derived; legacy product with established clinical use |
Curosurf has a significant competitive advantage in markets where clinicians value its concentrated initial dose and lower administration volume. Survanta and Infasurf retain clinical familiarity and institutional use in hospitals with established protocols.
The products are not automatically interchangeable in the same way as conventional small-molecule generics. Each has a distinct biological composition, manufacturing process, dose presentation, labeling history, and clinical-use profile. Formulary substitution requires institutional review and may depend on neonatal outcomes, dosing workflow, and supply contracts.
When does calfactant lose exclusivity?
Calfactant lost meaningful market exclusivity years ago. Infasurf was approved in 1998, so any standard five-year new-chemical-entity exclusivity would have expired no later than 2003. Any three-year clinical-investigation exclusivity associated with supplemental approval would also have expired long ago.
The principal patent position is similarly mature. Standard U.S. patent terms generally run 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and other statutory modifications. No active, commercially significant patent barrier is publicly associated with the original Infasurf approval in 2025.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Clinical investigation exclusivity |
Expired |
| Orphan-drug exclusivity |
No current commercial barrier identified |
| Core composition patents |
Expected to be expired |
| Orange Book strategy |
No meaningful current barrier apparent |
| Biosimilar exclusivity |
Not applicable to the product’s original approval pathway |
The product remains commercially protected by manufacturing know-how, regulatory history, clinical familiarity, supply reliability, and hospital relationships rather than by patent exclusivity.
What patents protect calfactant and Infasurf?
The principal defensible assets around calfactant are likely process and product-quality capabilities rather than active composition claims.
Calfactant is a complex biological mixture. Its commercial performance depends on:
- Bovine lung sourcing and qualification
- Extraction and lavage procedures
- Removal of contaminants and non-target proteins
- Phospholipid and surfactant-protein composition
- Sterility assurance
- Particle and suspension characteristics
- Fill-finish controls
- Stability and cold-chain management
- Batch-to-batch comparability
These factors can create a meaningful manufacturing barrier even when composition patents have expired. A competitor would need to demonstrate consistent quality, safety, potency, sterility, and clinical performance. That process is more difficult than copying a defined chemical active ingredient.
No publicly identified active patent estate gives Infasurf a durable monopoly over bovine pulmonary surfactant. The remaining protection is more accurately described as trade-secret, process, quality-system, regulatory, and customer-contract protection.
Does calfactant face generic or biosimilar competition?
Calfactant does not have a conventional biosimilar risk profile. Infasurf was approved as an NDA product rather than as a biologics license application product, and it is not positioned like a modern recombinant monoclonal antibody in the Purple Book.
A theoretical follow-on competitor could pursue an abbreviated or full application, depending on FDA classification and the product’s regulatory pathway. In practice, the barriers are substantial:
- The product is a complex natural mixture.
- The active material is not represented by a single chemically defined molecule.
- Source material and manufacturing controls affect the final product.
- Clinical use occurs in a high-acuity neonatal population.
- Hospitals may require robust comparative evidence before switching.
- The market may not support the development cost of a new entrant.
The more immediate competitive threat is not a standard AB-rated generic substitution. It is loss of formulary share to established surfactants, particularly Curosurf, or displacement by future synthetic or recombinant surfactants.
What is the FDA regulatory status of calfactant?
Infasurf remains an FDA-approved product for the prevention and treatment of neonatal RDS. Its regulatory value comes from a long post-approval record, established neonatal dosing, and continued clinical use.
| FDA and regulatory factor |
Assessment |
| Approval status |
Approved |
| Original pathway |
NDA |
| Pediatric use |
Core indication |
| Delivery system |
Intratracheal administration |
| Regulatory risk |
Low for the approved label; ongoing manufacturing compliance remains material |
| Label expansion potential |
Limited by the mature product category |
| Regulatory moat |
Historical approval and clinical experience, not exclusivity |
The main regulatory risks are manufacturing deviations, supply interruption, adverse-event scrutiny, and changes in neonatal treatment standards. A mature product can remain commercially important while having limited opportunity for label-based growth.
What manufacturing barriers protect calfactant?
Manufacturing is one of the strongest practical barriers surrounding calfactant.
Bovine-derived surfactant requires reliable biological sourcing and validated controls for infectious agents, impurities, potency, and composition. The manufacturer must maintain consistent performance across batches despite variation in biological starting material.
The production platform also requires specialized facilities and quality systems. A new manufacturer would face costs associated with:
- Qualified bovine tissue supply
- Animal-health and sourcing controls
- Extraction and purification equipment
- Sterile manufacturing
- Analytical characterization
- Stability testing
- Clinical and regulatory documentation
- Hospital launch and inventory support
These barriers do not prevent competition, but they reduce the likelihood of rapid, low-cost entry. They also support premium pricing relative to ordinary injectable generics, although hospital contracting can narrow the realized price difference.
How has the financial trajectory of calfactant developed?
Calfactant is a mature, cash-generating hospital product with limited public financial transparency. Its financial trajectory can be divided into four phases.
Launch and adoption: 1998 to the mid-2000s
Following FDA approval, Infasurf entered a market in which neonatal surfactant therapy was becoming standard care for premature infants with RDS. Revenue growth during this period would have depended on clinical adoption, expansion of neonatal intensive-care capacity, and replacement of older supportive-care approaches.
Mature branded period: mid-2000s to 2009
The product developed a stable hospital franchise. Demand was linked to neonatal admissions rather than discretionary prescribing, creating a relatively predictable volume base.
Ownership transition: 2009 onward
ONY Biotech acquired North American rights to Infasurf from Forest Laboratories. The transaction placed the product with a more focused specialty company whose commercial strategy centered on neonatal respiratory care rather than a diversified pharmaceutical portfolio.
Current mature-product period
The current financial model is likely characterized by:
- Stable but narrow demand
- Limited unit growth
- Contracting pressure from hospitals and group purchasing organizations
- High value placed on uninterrupted supply
- Manufacturing and quality costs that constrain margin expansion
- Low research-and-development requirements relative to a new biologic
- Limited upside from patent-protected price increases
The absence of public product-level revenue means no defensible dollar forecast can be assigned to Infasurf. The stronger business conclusion is that calfactant is a mature specialty asset with recurring demand and modest organic growth potential.
What revenue exposure does calfactant create for ONY Biotech?
Infasurf is central to ONY Biotech’s commercial identity and appears to be its principal established product. That concentration creates both value and risk.
The asset’s strengths are recurring neonatal demand, recognized clinical use, and a difficult manufacturing process. Its weaknesses are limited indication breadth, dependence on hospital purchasing, competition from Curosurf and Survanta, and the absence of current patent exclusivity.
For a private specialty-pharmaceutical company, a mature neonatal product can support predictable cash flow. It does not provide the same valuation profile as a protected biologic with expanding indications or a large outpatient market. Valuation is more likely to reflect:
- Net sales and retention rate
- Gross margin after manufacturing costs
- Hospital contract duration
- Supply reliability
- Geographic rights
- Regulatory inspection history
- Competitive pricing
- Pipeline assets that could reduce dependence on Infasurf
Which companies are challenging calfactant commercially?
The most important commercial challenger is Chiesi through Curosurf. Curosurf has broad international distribution and a concentrated dosing profile that can reduce initial administration volume.
AbbVie’s Survanta remains a relevant competitor, particularly in institutions with historical use and established protocols. The competitive landscape is therefore concentrated among three branded pulmonary surfactants rather than fragmented across numerous generic manufacturers.
No major patent litigation or Paragraph IV campaign is publicly associated with calfactant as of the available FDA and public-company record. The lack of Paragraph IV activity is consistent with an old product that has no commercially meaningful unexpired Orange Book patent barrier and a market too specialized to attract routine generic challenges.
What generic launch scenarios exist for calfactant?
A conventional generic launch would face limited substitution value because hospitals may not automatically substitute one biological surfactant for another. The more plausible scenarios are:
| Scenario |
Commercial effect |
| No follow-on entrant |
Infasurf retains a stable niche based on clinical familiarity and supply |
| Hospital-led switching to Curosurf |
Gradual share loss through formulary decisions |
| New complex generic or follow-on product |
Price pressure, but adoption remains dependent on clinical evidence |
| Manufacturing disruption |
Temporary demand surge for available competitors |
| New synthetic surfactant |
Potential long-term displacement if efficacy, dosing, and logistics improve |
| Declining premature-birth rates |
Volume pressure in developed markets |
A successful entrant would need more than regulatory approval. It would need neonatal trial credibility, reliable inventory, competitive contracting, and an intensive-care sales infrastructure.
How does calfactant compare with competing surfactant patent estates?
Calfactant, beractant, and poractant alfa all operate in a mature competitive field where practical barriers exceed current composition-patent protection.
| Factor |
Calfactant |
Curosurf |
Survanta |
| Core patent strength |
Low due product age |
Mature; current value mainly commercial and regulatory |
Mature; current value mainly commercial and regulatory |
| Manufacturing complexity |
High |
High |
High |
| Biosimilar exposure |
Limited conventional exposure |
Limited conventional exposure |
Limited conventional exposure |
| Hospital switching risk |
Moderate to high |
Moderate to high |
Moderate |
| International position |
More concentrated in North America |
Broad international presence |
Broad historical recognition |
| Primary moat |
Supply, clinical familiarity, manufacturing |
Brand, dose profile, global infrastructure |
Legacy use and institutional familiarity |
Curosurf has the strongest international commercial platform. Infasurf’s position is more dependent on U.S. market execution and continued hospital acceptance.
Key Takeaways
- Calfactant is the active ingredient in Infasurf, an FDA-approved bovine pulmonary surfactant for premature infants with or at risk of neonatal RDS.
- FDA approval dates to 1998, and regulatory and patent exclusivity have expired.
- The product has no obvious current Orange Book patent barrier capable of preventing competition.
- Manufacturing know-how, biological sourcing, quality controls, and clinical experience are the main remaining barriers.
- Standalone Infasurf revenue and profitability are not publicly disclosed.
- The product has stable demand but limited growth because its patient population is narrow and hospital purchasing is concentrated.
- Curosurf is the strongest commercial competitor, while Survanta remains a recognized alternative.
- Generic or biosimilar substitution is less likely than formulary-driven competition among established surfactants.
- The financial profile is that of a mature specialty hospital asset: recurring demand, modest growth, meaningful supply-chain value, and limited patent-driven pricing power.
FAQs about calfactant market and patent risk
Is calfactant still commercially available?
Infasurf remains an FDA-approved neonatal surfactant associated with ONY Biotech. Commercial availability depends on ongoing manufacturing and distribution.
Is Infasurf listed in the FDA Orange Book?
Infasurf is an NDA-approved drug product. The product’s commercial position does not appear to depend on any active, high-value Orange Book patent barrier.
Can a company launch a generic version of Infasurf?
A follow-on product could be developed, but the complex biological composition, specialized manufacturing, neonatal clinical requirements, and limited market size make conventional generic entry difficult.
Is calfactant a biologic for biosimilar purposes?
Calfactant is a biologically derived drug, but Infasurf was approved through an NDA pathway rather than the modern BLA pathway typically associated with biosimilars. Its competitive risk is therefore not equivalent to that of a large-molecule biologic such as a monoclonal antibody.
What is the main investment risk for a calfactant-focused company?
The main risks are product concentration, hospital price pressure, competition from Curosurf, manufacturing disruption, and limited opportunity to expand the indication base.
References
-
U.S. Food and Drug Administration. (2023a). Infasurf (calfactant) intratracheal suspension: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Drugs@FDA: Infasurf, NDA 020972. FDA.
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024c). Purple Book: Database of licensed biological products. FDA.
-
ONY Biotech, Inc. (2009). ONY Biotech acquires North American rights to Infasurf from Forest Laboratories. Company announcement.
-
Chiesi Farmaceutici S.p.A. (2024). Curosurf product information. Chiesi.
-
AbbVie Inc. (2024). Survanta prescribing information. AbbVie.
